Early Intervention With Intravenous or Pulse Oral Vitamin D Therapy Is More Effective in the Treatment of Secondary Hyperparathyroidism

被引:3
作者
Yamada, Shunsuke
Taniguchi, Masatomo [1 ]
Tokumoto, Masanori
Tsuruya, Kazuhiko [2 ]
Hirakata, Hideki [3 ]
Iida, Mitsuo
机构
[1] Kyushu Univ, Dept Med & Clin Sci, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Dept Integrated Therapy Chron Kidney Dis, Grad Sch Med Sci, Fukuoka 8128582, Japan
[3] Fukuoka Red Cross Hosp, Div Nephrol, Fukuoka, Japan
关键词
Early intervention; Hemodialysis; Kidney Disease Outcomes Quality Initiative clinical practice guidelines; Parathyroid hormone; Secondary hyperparathyroidism; Vitamin D; PARATHYROID-HORMONE LEVELS; MINERAL METABOLISM; BONE METABOLISM; KIDNEY-DISEASE; MORTALITY RISK; ASSOCIATION; OUTCOMES; GLAND; PHOSPHATE; RECEPTOR;
D O I
10.1111/j.1744-9987.2010.00817.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The K/DOQI clinical practice guidelines recommend vitamin D therapy should be started when the intact parathyroid hormone (iPTH) exceeds 300 pg/mL in patients with secondary hyperparathyroidism. To examine whether the effect of vitamin D therapy on mineral metabolism and parathyroid gland growth varies according to the stage of secondary hyperparathyroidism and iPTH level, 47 patients with secondary hyperparathyroidism received either intravenous or pulse oral vitamin D therapy. The patients were divided into two groups based on the iPTH level at the start of vitamin D therapy: the P-< 300 group (N = 23) with iPTH < 300 pg/mL; and the P >= 300 group (N = 24) with iPTH >= 300 pg/mL. We examined serial changes in several serum mineral parameters and parathyroid gland volume and the cumulative incidence of parathyroidectomy in the first two years. Serum calcium, phosphorus, calcium-phosphorus product, and iPTH levels of the P >= 300 group were significantly higher than those of the P-< 300 group, and could not be maintained within the target ranges set by the K/DOQI guidelines. In contrast, the serum levels of phosphorus, calcium-phosphorus product, and iPTH were maintained within the target ranges and the parathyroid gland did not enlarge in the P-< 300 group. The cumulative incidence of parathyroidectomy in the P >= 300 group was significantly higher than in the P-< 300 group. Early intervention with intravenous or pulse oral vitamin D therapy at serum iPTH < 300 pg/mL can control serum phosphorus, calcium-phosphorus product, and PTH levels to the target ranges and slow the progression of secondary hyperparathyroidism.
引用
收藏
页码:424 / 431
页数:8
相关论文
共 25 条
[1]   Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease:: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units [J].
Arenas, M. Dolores ;
Alvarez-Ude, Fernando ;
Gil, M. Teresa ;
Soriano, Antonio ;
Egea, Juan Jose ;
Millan, Isabel ;
Amoedo, M. Luisa ;
Muray, Salome ;
Carreton, M. Antonia .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (06) :1663-1668
[2]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[3]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[4]   On the evolving nature of understanding dialysis-related disorders [J].
Eknoyan, G ;
Lindberg, JS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) :S1-S3
[5]   SERIAL EVALUATION OF PARATHYROID SIZE BY ULTRASONOGRAPHY IS ANOTHER USEFUL MARKER FOR THE LONG-TERM PROGNOSIS OF CALCITRIOL PULSE THERAPY IN CHRONIC DIALYSIS PATIENTS [J].
FUKAGAWA, M ;
KITAOKA, M ;
YI, H ;
FUKUDA, N ;
MATSUMOTO, T ;
OGATA, E ;
KUROKAWA, K .
NEPHRON, 1994, 68 (02) :221-228
[6]   Management of patients with advanced secondary hyperparathyroidism: the Japanese approach [J].
Fukagawa, M ;
Kazama, JJ ;
Shigematsu, T .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (09) :1553-1557
[7]   DECREASED 1,25-DIHYDROXYVITAMIN-D(3) RECEPTOR DENSITY IS ASSOCIATED WITH A MORE SEVERE FORM OF PARATHYROID HYPERPLASIA IN CHRONIC UREMIC PATIENTS [J].
FUKUDA, N ;
TANAKA, H ;
TOMINAGA, Y ;
FUKAGAWA, M ;
KUROKAWA, K ;
SEINO, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (03) :1436-1443
[8]  
Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
[9]   A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism [J].
Goodman, WG ;
Frazao, JM ;
Goodkin, DA ;
Turner, SA ;
Liu, W ;
Coburn, JW .
KIDNEY INTERNATIONAL, 2000, 58 (01) :436-445
[10]   DEVELOPMENT OF ADYNAMIC BONE IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM AFTER INTERMITTENT CALCITRIOL THERAPY [J].
GOODMAN, WG ;
RAMIREZ, JA ;
BELIN, TR ;
CHON, Y ;
GALES, B ;
SEGRE, GV ;
SALUSKY, IB .
KIDNEY INTERNATIONAL, 1994, 46 (04) :1160-1166